Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$157.96 USD
+1.05 (0.67%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $158.18 +0.22 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 401 - 420 ( 663 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on PDUFA Date as Sarepta Reports 1Q16; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Despite a Groundswell of Hope, Door Appears Shut on Eteplirsen for Now; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL; FDA Doubles Down on No; Stepping to the Sidelines due to Regulatory Risk; PT to $14
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lifesciences Review: Down but not out
Provider: HYBRIDAN LLP
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Announces Consolidation Plans but Still No News on an Advisory Panel; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Waiting on FDA as Sarepta Reports 4Q15 Results; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Waiting is the Hardest Part - Continued Uncertainty Overshadows Eteplirsen; Reiterating OUTPERFORM but Lowering PT to $32
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Curiouser and Curiouser - A Deeper Look into the Eteplirsen Briefing Documents; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D